Terminated registry of PAH (pulmonary arterial hypertension) patients who were treated with parenteral prostanoids.
start of the project: January 2010
end of the project: July 2018
Parenteral prostanoids are prescribed to patients diagnosed with pulmonary arterial hypertension (PAH) in order to maximize their exercise tolerance and to minimise their symptoms. PAH is a very rare disease with a prevalence of 1.5-2.6 patients per 100.000 population. It is therefore desirable to monitor and to assess the safety of patients treated by a specific treatment regularly and on a central level.
PAH is a disease of lung arterioles which is characterised by an increase of mean arterial pressure in the pulmonary artery (>25mm Hg at rest, >30mm Hg during exercise). It is also characterised by an increased pulmonary vascular resistance (>3 WU, Wood units).
Without adequate treatment, PAH progressively leads to heart failure and death. Median survival rate in untreated patients is around 2.8 years. Symptoms are non-specific, especially in early stages of the disease. Severity of symptoms considerably correlates with the prognosis of a given patient. The most common symptoms involve exertional dyspnoea, fatigue, chest pain and syncope.
PROPEL – the Prospective Registry Of ParEnteraL prostanoids – was focused on the collection of clinical data on PAH patients as well as data on therapeutic effects and safety of parenteral prostanoids.
Primary objective of the project:
Secondary objectives of the project:
Other important information: